Skip Navigation

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

Nikhil Wagle, MD
December 10, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, report scientists from Dana-Farber Cancer Institute. “It was surprising to discover...
Read Story
  • Explore the Newsroom

    News Releases

    See our news releases about cancer care, cancer research, and cancer treatment by Dana-Farber Cancer Institute doctors and researchers.

    News Coverage

    Get the latest news about Dana-Farber Cancer Institute.

    News Videos

    Watch brief explainer videos focusing on science, research, and advances in cancer, featuring Dana-Farber Cancer Institute doctors and researchers.

    For Journalists

    Dana-Farber welcomes the opportunity to partner with journalists. Find contacts, resources, and more.

    Publications

    Read the latest issues of Dana-Farber publications.

    Insight Blog

    Insight features the latest in cancer care and research news from Dana-Farber.

    Dana-Farber Spotlight

    Sign up to receive Dana-Farber Spotlight, our email newsletter.
    View the current issue
    Subscribe now
    Unsubscribe from mailings
  • View Our Events Calendar

    View Dana-Farber's calendar of events, including nutrition seminars, health and wellness classes, patient education, community outreach and fundraising events, and support groups.

    caregiver support group


    Participants in a caregiver support group